E Fund Management Co. Ltd. Sells 2,638 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

E Fund Management Co. Ltd. cut its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 4.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 54,094 shares of the company’s stock after selling 2,638 shares during the period. E Fund Management Co. Ltd.’s holdings in Recursion Pharmaceuticals were worth $533,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. ARK Investment Management LLC grew its stake in shares of Recursion Pharmaceuticals by 200.4% in the fourth quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock valued at $203,651,000 after buying an additional 13,777,689 shares in the last quarter. FMR LLC grew its position in shares of Recursion Pharmaceuticals by 134.4% in the 3rd quarter. FMR LLC now owns 10,689,532 shares of the company’s stock valued at $81,775,000 after acquiring an additional 6,129,935 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Recursion Pharmaceuticals by 161.2% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock valued at $90,749,000 after acquiring an additional 5,680,656 shares during the period. Vanguard Group Inc. increased its stake in shares of Recursion Pharmaceuticals by 37.7% during the 3rd quarter. Vanguard Group Inc. now owns 15,506,834 shares of the company’s stock worth $118,627,000 after purchasing an additional 4,247,002 shares during the last quarter. Finally, Rafferty Asset Management LLC lifted its stake in Recursion Pharmaceuticals by 244.7% in the 3rd quarter. Rafferty Asset Management LLC now owns 1,104,526 shares of the company’s stock valued at $8,450,000 after purchasing an additional 784,113 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded down $0.20 on Wednesday, reaching $8.59. The stock had a trading volume of 2,554,520 shares, compared to its average volume of 6,255,742. The company has a market cap of $2.02 billion, a P/E ratio of -5.54 and a beta of 0.85. The firm has a fifty day moving average of $9.63 and a two-hundred day moving average of $9.26. Recursion Pharmaceuticals, Inc. has a 1-year low of $4.92 and a 1-year high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. The business had revenue of $10.89 million for the quarter, compared to the consensus estimate of $12.37 million. Research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Michael Secora sold 23,124 shares of the business’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $7.58, for a total value of $175,279.92. Following the completion of the sale, the chief financial officer now directly owns 1,231,055 shares in the company, valued at $9,331,396.90. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, COO Tina Marriott sold 8,000 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $14.89, for a total transaction of $119,120.00. Following the completion of the sale, the chief operating officer now owns 639,982 shares of the company’s stock, valued at $9,529,331.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Secora sold 23,124 shares of the stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $7.58, for a total transaction of $175,279.92. Following the sale, the chief financial officer now owns 1,231,055 shares in the company, valued at approximately $9,331,396.90. The disclosure for this sale can be found here. Insiders have sold a total of 352,946 shares of company stock worth $3,485,453 in the last quarter. Corporate insiders own 15.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on RXRX shares. Needham & Company LLC reissued a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. KeyCorp increased their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. Finally, TD Cowen assumed coverage on shares of Recursion Pharmaceuticals in a research report on Friday, January 26th. They set a “market perform” rating for the company. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $12.75.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.